Company Description
Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States.
Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer’s disease; and AL050, a GCase enzyme replacement therapy in preclinical development for the potential treatment of Parkinson’s disease and Lewy body dementia in patients having GBA1 gene mutations.
The company also develops its preclinical and research pipeline comprising AL064, a tau siRNA for Alzheimer’s disease and other tauopathies; ADP062-ABC, an alpha-synuclein siRNA for Parkinson’s disease; and ADP065-ABC, an NLRP3 siRNA for neurodegenerative conditions.
It has a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of progranulin-elevating monoclonal antibodies, including Latozinemab and Nivisnebart.
The company was founded in 2013 and is headquartered in South San Francisco, California.
| Country | United States |
| Founded | 2013 |
| IPO Date | Feb 7, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 103 |
| CEO | Arnon Rosenthal |
Contact Details
Address: 131 Oyster Point Boulevard, Suite 600 South San Francisco, California 94080 United States | |
| Phone | 415 231 5660 |
| Website | alector.com |
Stock Details
| Ticker Symbol | ALEC |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $19.00 |
| CIK Code | 0001653087 |
| CUSIP Number | 014442107 |
| ISIN Number | US0144421072 |
| Employer ID | 82-2933343 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Arnon Rosenthal Ph.D. | Co-Founder, Chief Executive Officer and Director |
| Neil Berkley M.B.A., M.S. | Chief Financial Officer and Chief Business Officer |
| Katie Hogan | Senior Director of Corporate Communication and Investor Relations |
| Danielle Pasqualone J.D., Ph.D. | General Counsel |
| Clare Hunt M.B.A. | Chief People and Places Officer |
| Kristina Cutter M.P.H. | Chief Development Officer |
| Giacomo Salvadore M.D. | Chief Medical Officer |
| Dr. Hua Long DABT, Ph.D. | Senior Vice President and Head of Research |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 10, 2026 | 144 | Filing |
| Mar 3, 2026 | 144 | Filing |
| Feb 27, 2026 | 144 | Filing |
| Feb 27, 2026 | 144 | Filing |
| Feb 27, 2026 | 144 | Filing |
| Feb 26, 2026 | 144 | Filing |
| Feb 25, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 25, 2026 | 10-K | Annual Report |
| Feb 25, 2026 | 8-K | Current Report |
| Feb 17, 2026 | SCHEDULE 13G/A | Filing |